Education
About Us
Working with TipRanks
Follow Us
Precipio Inc (PRPO)
NASDAQ:PRPO
PRPO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.90 - $22.38
Previous CloseN/A
Volume11.00
Average Volume (3M)19.81K
Market Cap
$28.21M
Enterprise Value$19.17M
Total Cash (Recent Filing)$1.13M
Total Debt (Recent Filing)$2.61M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding1,619,584
10 Day Avg. Volume22,820
30 Day Avg. Volume19,811
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit2.02
Enterprise Value/Ebitda-37.59
Forecast
1Y Price Target
$22.00Price Target Upside26.29% Upside
Rating ConsensusHold
Number of Analyst Covering0
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $3.90 and its highest was $22.38 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $28.21M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Nov 24, 2025 which is in 55 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Aug 13, 2025. The company reported $0.046 earnings per share for the quarter, beating the consensus estimate of N/A by $0.046.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Undervalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,619,584 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of $0.046 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.939%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.00 (26.29% Upside)
$22.00 (26.29% Upside)
Insider Transactions
Sold Shares
Worth $123.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
166.23%
12-Months-Change
Fundamentals
Return on Equity
-14.76%
Trailing 12-Months
Asset Growth
8.65%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Precipio shows strong financial and operational improvements, particularly in revenue growth and gross margin enhancement. While there were minor setbacks, such as a slight decline in product gross margin and operational challenges faced by the Products division, the company has demonstrated resilience and strategic foresight to overcome these issues. The overall sentiment is positive, with significant progress towards breakeven and strategic initiatives in place to support continued growth.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
11.83% Insiders
1.96% Mutual Funds
1.72% Other Institutional Investors
83.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---